Sun Pharma gets USFDA nod for prostate cancer drug

Drug major Sun Pharmaceutical IndustriesNSE 2.34 %' subsidiary has received approval from the US health regulator for YONSA, used for treatment of a form of prostate cancer. 

Sun Pharma had acquired YONSA from Churchill Pharmaceuticals and will commercialise the drug in the US. 

In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said "one of Sun Pharma's wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA)  for YONSA."

YONSA (abiraterone acetate) is a novel formulation in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the company said. 

Sun Pharma said Churchill is eligible to receive upfront and sales-linked milestone payments as well as royalties on sales pursuant to an agreement between the two companies to commercialise YONSA in the US. 

YONSA in combination with methylprednisolone was filed as a new drug application (NDA) and will be promoted as a branded product in the US, Sun Pharma added. 



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer